Virus characteristics predict HIV treatment efficacy with antibody treatment

November 06, 2019

BOSTON - Current HIV-1 therapies have been proven to be highly effective in slowing the progression of the virus in the body with only minimal side effects. The daily antiretroviral therapy (ART) uses a combination of HIV-1 medicines. A proportion of patients diagnosed with HIV-1, however, cannot take the ART for many reasons. An alternative option includes antibody-based treatments that are currently being developed, however it is difficult to predict those that would be most appropriate for these more expensive treatments. Now published in the Journal of Virology, research at Boston Medical Center (BMC) has discovered specific virus characteristics that can help predict the efficacy of HIV-1 treatments using antibody-based treatments.

Led by Manish Sagar, MD, an infectious diseases physician at BMC, HIV-1 virus characteristics were identified to predict treatment efficacy with a specific antibody treatment using sequence-based methods. The identified virus characteristics may be used to determine if a patient is a good or poor candidate for specific antibody-based treatments in the future, reducing time and cost involved in treating the virus.

Antibody treatments bind the HIV-1 envelope protein that protects the virus and helps it avoid the immune system response. These envelope proteins also have extensive DNA sequence variation that provides virus information and whether a treatment would be effective or not. It is difficult to predict if an antibody-based therapy will be effective based on knowing the envelope sequence alone, so sequence information is commonly obtained before patients are started on HIV-1 treatments to confirm that their virus will be susceptible to the prescribed therapies.

In the study, HIV-1 envelope sequence motifs were identified that predict treatment efficacy with a certain type of antibody treatment.

"These findings will allow physicians to make better-informed decisions on treatment plans for patients with HIV-1, ultimately treating the virus to slow it down earlier, " says Sagar, also an associate professor of medicine and microbiology at Boston University School of Medicine. "Making this process more efficient will only improve patient care, while reducing the time and money spent on finding the right treatment for these patients."

Antibody-based therapies that require less frequent doping are effective against drug-resistant variants, and may strengthen humoral responses, essential for defense against bacterial pathogens.
-end-
Funding for this study was provided by the National Institute of Health (grant number AI122209).

About Boston Medical Center


Boston Medical Center is a private, not-for-profit, 514-bed, academic medical center that is the primary teaching affiliate of Boston University School of Medicine. It is the largest and busiest provider of trauma and emergency services in New England. Boston Medical Center offers specialized care for complex health problems and is a leading research institution, receiving more than $116 million in sponsored research funding in fiscal year 2017. It is the 15th largest recipient of funding in the U.S. from the National Institutes of Health among independent hospitals. In 1997, BMC founded Boston Medical Center Health Plan, Inc., now one of the top ranked Medicaid MCOs in the country, as a non-profit managed care organization. Boston Medical Center and Boston University School of Medicine are partners in the Boston HealthNet - 14 community health centers focused on providing exceptional health care to residents of Boston. For more information, please visit http://www.bmc.org.

Boston Medical Center

Related Microbiology Articles from Brightsurf:

79 Fellows elected to the American Academy of Microbiology
In January of 2015, the American Academy of Microbiology elected 79 new Fellows.

New discovery in the microbiology of serious human disease
Previously undiscovered secrets of how human cells interact with a bacterium which causes a serious human disease have been revealed in new research by microbiologists at The University of Nottingham.

4 cells turn seabed microbiology upside down
With DNA from just four cells, researchers reveal how some of the world's most abundant organisms play a key role in carbon cycling in the seabed.

87 scientists elected to the American Academy of Microbiology
Eighty-seven microbiologists have been elected to Fellowship in the American Academy of Microbiology.

Tips from the journals of the American Society for Microbiology
This release includes information about these articles: Specific Bacterial Species May Initiate, Maintain Crohn's; Bacteria Involved in Sewer Pipe Corrosion Identified; Antibodies to Immune Cells Protect Eyes In Pseudomonas Infection; Dangerous Form of MRSA, Endemic In Many US Hospitals, Increasing in UK.

Tips from the journals of the American Society for Microbiology
Upcoming articles from the journals of the American Society for Microbiology include:

Microbiology brought to life in Nottingham
Antimicrobial insect brains, mouth bacteria behaving badly and the hundreds of microbial communities that lurk in household dust are just some of the highlights at the Society for General Microbiology's autumn meeting in Nottingham next week.

Tips from the journals of the American Society for Microbiology
The following are tips from the journals of the American Society for Microbiology:

Tips from the journals of the American Society for Microbiology
The following are tips from the Journals of the American Society for Microbiology:

New text focuses on microbiology of historic artifacts
Historic and culturally important artifacts, like all materials, are vulnerable to microbial attack.

Read More: Microbiology News and Microbiology Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.